Compare Davita Inc (DVA) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs SpaceX — how do they compare? Davita Inc trades at $230.55 (market cap $14.92B), while SpaceX trades at $137.54 (market cap $1.79T). The key difference: SpaceX is far larger — about 120× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| DVA | SPCX | |
|---|---|---|
Market Cap | $14.92B | $1.79T |
Sector | Health | Technology |
52-Week High | $235.71 | $202.09 |
52-Week Low | $103.87 | $135.00 |
Enterprise Value | $27.47B | $1.81T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPCX trades at $139.14, down 4.33% over 24 hours, reflecting post-IPO volatility. The stock shows bearish technical signals with key support at $137 and resistance at $141. Fundamentally, the company reported 2025 revenue of $18.67B but a net loss of $4.94B, with negative profitability margins. Recent news highlights Nasdaq-100 inclusion and new Starlink partnerships, providing mixed sentiment amid high valuation concerns.
Outlook remains speculative with analyst consensus bullish (100% buy rating) and a $239.23 price target, but risks include sustained losses, high P/S ratio of 94.3, and competitive pressures. Investment appeal hinges on future profitability and execution of growth initiatives in the space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
